Jan Mares
Palacký University, Olomouc
33 Papers
55 Citations
Jan Mares is an academic researcher from Palacký University, Olomouc. The author has contributed to research in topics: Medicine & Multiple sclerosis. The author has an hindex of 13, co-authored 32 publications. Previous affiliations of Jan Mares include University of California, San Francisco.
Chat about Author
Papers
Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO study
Paul O'Connor,Giancarlo Comi,Mark S. Freedman,Aaron E. Miller,Ludwig Kappos,Jean-Pierre Bouchard,Christine Lebrun-Frenay,Jan Mares,Myriam Benamor,Karthinathan Thangavelu,Jinjun Liang,Philippe Truffinet,Victoria J. Lawson,Jerry S. Wolinsky +13 more
TL;DR: In the TEMSO extension, safety observations were consistent with the core trial, with no new or unexpected AEs in patients receiving teriflunomide for up to 9 years.
121
Current therapeutic landscape in multiple sclerosis: an evolving treatment paradigm.
TL;DR: Development of disease-modifying agents in MS continues to be successful, but treatment algorithms need to take new developments into account.
81
Targeting B Cells to Modify MS, NMOSD, and MOGAD: Part 1.
Jonas Graf,Jan Mares,Michael L. Barnett,Orhan Aktas,Philipp Albrecht,Scott S. Zamvil,Hans Peter Hartung +6 more
TL;DR: This review more closely examines the clinical development of CD20 depletion and the pioneering contribution of rituximab to understand the significance of this breakthrough in the context of the current MS therapeutic armamentarium.
81
CSF markers of neurodegeneration in Parkinson’s disease
Hana Přikrylová Vranová,Jan Mares,Martin Nevrlý,David Stejskal,Jana Zapletalová,Petr Hluštík,Petr Kaňovský +6 more
TL;DR: Significantly higher tau protein and clusterin CSF levels in the group of PD patients with disease duration of <2 years probably reflect the fact that most neurodegenerative changes in PD patients occur in the initial stage of disease.
59
Tau protein, beta-amyloid1–42 and clusterin CSF levels in the differential diagnosis of Parkinsonian syndrome with dementia
Hana Přikrylová Vranová,Eva Hényková,Michaela Kaiserová,Kateřina Menšíková,Miroslav Vastik,Jan Mares,Petr Hluštík,Jana Zapletalová,Miroslav Strnad,David Stejskal,Petr Kaňovský +10 more
TL;DR: The results of the present study support the role of clusterin in PD pathogenesis as the decreasing CSF beta-amyloid1-42 levels in the order PDD, DLB and AD may relate to the increasing presence of AD pathology in these disorders.
58